QUDEXY XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUDEXY XR (QUDEXY XR).
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
| Metabolism | Primarily hepatic via CYP3A4; also undergoes hydrolysis to carbamazepine epoxide (active metabolite) and further glucuronidation. |
| Excretion | Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%). |
| Half-life | Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks). |
| Protein binding | Protein binding is 13-17% (primarily to albumin); low binding minimizes displacement interactions. |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution primarily in total body water. |
| Bioavailability | Oral bioavailability is approximately 100% for the extended-release formulation; food does not affect absorption. |
| Onset of Action | Oral: onset of seizure reduction typically observed within 1-2 weeks of therapeutic dosing; maximal effect may require 4-8 weeks. |
| Duration of Action | Duration of action is approximately 12 hours; twice-daily dosing maintains therapeutic concentrations; missed doses may increase seizure risk. |
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl 30-49 mL/min: reduce by 50%. CrCl <30 mL/min: not recommended. Hemodialysis: supplemental dose of 50-100 mg after each dialysis session. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated. |
| Pediatric use | Ages 2-17: initial 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target 200-400 mg/day in two divided doses. Weight-based not required; use same dose as adults. |
| Geriatric use | Start at 25 mg orally twice daily; consider slower titration due to age-related renal decline. Monitor renal function and adjust per CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QUDEXY XR (QUDEXY XR).
| Breastfeeding | Topiramate is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.86. Infant serum levels can reach 10-20% of maternal levels. Adverse effects reported include diarrhea, somnolence, and poor feeding. Use with caution; monitor infant for signs of sedation, poor feeding, and weight loss. The benefits of breastfeeding should be weighed against the potential risks. |
| Teratogenic Risk | Topiramate is associated with an increased risk of oral clefts (cleft lip with or without cleft palate) in infants exposed during the first trimester. The risk is dose-dependent, with higher doses (>200 mg/day) conferring greater risk. In the second and third trimesters, topiramate exposure may be associated with reduced fetal growth and low birth weight. Topiramate is pregnancy category D (positive evidence of human fetal risk). |
■ FDA Black Box Warning
QUDEXY XR is associated with an increased risk of suicidal thoughts or behavior in patients taking antiepileptic drugs. Monitor for emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behavior.
| Serious Effects |
History of bone marrow depression; known hypersensitivity to carbamazepine or tricyclic compounds; concomitant use of MAOIs or within 14 days of MAOI discontinuation; history of hypersensitivity to any antiepileptic drug that produces phenytoin-like metabolites (e.g., oxcarbazepine, eslicarbazepine); hypovolemic hyponatremia; acute intermittent porphyria.
| Precautions | Suicidal behavior and ideation; serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis); multi-organ hypersensitivity reactions; decreased serum sodium; hepatotoxicity; hematologic effects (aplastic anemia, agranulocytosis); dizziness, somnolence, ataxia; withdrawal seizures; ophthalmic effects (pupillary defects, blurred vision); interaction with oral contraceptives; use in pregnancy (fetal harm); interaction with other drugs (e.g., CNS depressants, MAOIs). |
Loading safety data…
| Fetal Monitoring | Women of childbearing potential should be counseled about the risks of topiramate during pregnancy and the use of effective contraception. If pregnancy occurs, prenatal monitoring should include high-resolution ultrasound to detect oral clefts (typically at 18-20 weeks gestation). Monitor fetal growth throughout pregnancy. Neonates should be monitored for withdrawal symptoms (hyperexcitability, irritability) after birth. |
| Fertility Effects | Topiramate may affect fertility. In women, it can disrupt the hypothalamic-pituitary-ovarian axis, leading to menstrual irregularities, anovulation, and decreased fertility. In men, topiramate has been associated with decreased sperm count and motility in animal studies; human data are limited. Reversible upon discontinuation. |